PRLD
USDPrelude Therapeutics Incorporated Common Stock
Preço em tempo real
Gráfico de preços
Métricas-chave
Métricas de mercado
Abertura
$1.190
Máximo
$1.280
Mínimo
$1.173
Volume
1.13M
Fundamentos da empresa
Capitalização de mercado
71.5M
Setor
Biotecnologia
País
United States
Estatísticas de negociação
Volume médio
1.27M
Bolsa de valores
NMS
Moeda
USD
Faixa de 52 semanas
Notícias relacionadas
Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
Incyte secures an exclusive option to acquire Prelude's mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with
Prelude Therapeutics Announces Strategic Business Update
Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement
Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting
WILMINGTON, Del., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD) ("Prelude" or the "Company"), a clinical-stage precision oncology company, today announced the publication of two
Ações relacionadas
TTMI
TTM Technologies Inc.
BST
BlackRock Science and Technology Trust Common Shares of Beneficial Interest
VERU
Veru Inc.
BDJ
Blackrock Enhanced Equity Dividend Trust
UAVS
AgEagle Aerial Systems Inc.
Mantenha-se atualizado
Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.